Skip to content

clinical reseach of Zuojin pill reversion to multidrug resistance of colorectal cancer based on orthogonal design optimization

clinical reseach of Zuojin pill reversion to multidrug resistance of colorectal cancer based on orthogonal design optimization

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16007804
Enrollment
Unknown
Registered
2016-01-20
Start date
2016-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Tharapy:Zuojin partical
Control:placebo

Sponsors

Shuguang Hospital affiliated with Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) clear cytology or pathological diagnosis of colorectal cancer patients; (2) all gender, aged 18 to 75 years old; (3) body condition scoring KPS 80 or higher.Expected survival period of 6 months or more; (4) for clinical stage IIb - IV to do chemotherapy, biopsy and/or peripheral blood test P - gp protein is positive, the diagnosis of multiple drug resistance of colorectal cancer patients; (5) Always have repeatedly chemotherapy, and 6 months in patients with recurrence or metastasis; (6) No serious heart, liver, kidney, hematopoietic system disease, and other factors affecting drug evaluation; Observe all landowners voluntarily accept this study plan, good adherence, clear-thinking, clearly stated, language and sensory response to normal; (7) Understanding the situation of this study and signed informed consent, to follow-up.

Exclusion criteria

Exclusion criteria: Have any of the following items are not included in this test: (1) does not conform to the diagnosis and inclusion criteria, diagnosis unknown;Pathological types for non epithelial tumors such as stromal tumor, colon malignant melanoma, colon smooth muscle sarcoma, etc.; (2) has serious heart disease of cardiovascular system, urinary system diseases, diseases of the blood system, digestive system disease, can't tolerate the patients clinical trials; Women during pregnancy or lactation;Mental disorders are not easy to control; (3) observed during disease progression, life-threatening, patients can't cooperate with the follow-up; (4) no detection, with poor adherence, patients lost to follow-up, to give up treatment.

Design outcomes

Primary

MeasureTime frame
PFS;overall response rate;

Secondary

MeasureTime frame
resistance protein;quality of life;TCM symdrom;

Countries

China

Contacts

Public ContactZHAO Gang
drzhaogang@126.com+86 18916081988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026